{"id":2232,"date":"2022-06-15T10:42:49","date_gmt":"2022-06-15T10:42:49","guid":{"rendered":"https:\/\/emergencydrug.com\/?post_type=product&#038;p=2232"},"modified":"2024-09-26T11:11:57","modified_gmt":"2024-09-26T11:11:57","slug":"caboxen-cabozantinib-80-mg","status":"publish","type":"product","link":"https:\/\/emergencydrug.com\/ar\/shop\/caboxen-cabozantinib-80-mg\/","title":{"rendered":"Caboxen (Cabozantinib) 80 MG &#8211; 30 Capsules"},"content":{"rendered":"<p><strong>Product Features<\/strong><\/p>\n<table width=\"547\">\n<tbody>\n<tr>\n<td width=\"150\">Product Name<\/td>\n<td width=\"24\">:<\/td>\n<td width=\"450\">Caboxen<\/td>\n<\/tr>\n<tr>\n<td width=\"150\">Generic Name<\/td>\n<td width=\"24\">:<\/td>\n<td width=\"450\">Cabozantinib<\/td>\n<\/tr>\n<tr>\n<td width=\"150\">Manufacture<\/td>\n<td width=\"24\">:<\/td>\n<td width=\"450\">Everest Pharma Ltd<\/td>\n<\/tr>\n<tr>\n<td width=\"150\">Available Pack Size<\/td>\n<td width=\"24\">:<\/td>\n<td width=\"450\">30\u2019s Pot<\/td>\n<\/tr>\n<tr>\n<td width=\"150\">Available Strength<\/td>\n<td width=\"24\">:<\/td>\n<td width=\"450\">80 mg<\/td>\n<\/tr>\n<tr>\n<td width=\"150\">Registrations<\/td>\n<td width=\"24\">:<\/td>\n<td width=\"450\">Export Only<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">Caboxen 80 mg is a targeted therapy. It is an oral receptor tyrosine kinase inhibitor. Cabozantinib treats metastatic medullary thyroid cancer (MTC), advanced renal cell carcinoma, and patients with hepatocellular cancer (HCC) who have previously received sorafenib.\u00a0<\/span><\/p>\n<div id=\"indications\">\n<h3 class=\"ac-header\">Indications:<\/h3>\n<p>Caboxen is used:<\/p>\n<ul>\n<li><span data-preserver-spaces=\"true\">To treat advanced renal cell carcinoma (RCC; a type of cancer that begins in the cells of the kidneys).<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">In combination with Nivolumab (Opdivo) to treat advanced RCC in patients who have not yet received treatment for RCC.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">To treat hepatocellular carcinoma (HCC; a type of liver cancer) in people previously treated with sorafenib.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Treat a specific type of thyroid cancer in adults and children 12 years of age and older that has spread to nearby tissues or other parts of the body has not responded to previous a treatment and cannot be treated with radioactive iodine.\u00a0<\/span><\/li>\n<\/ul>\n<div id=\"mode_of_action\">\n<h3 class=\"ac-header\">Pharmacology:<\/h3>\n<p><span data-preserver-spaces=\"true\">In vitro biochemical and cellular assays have shown that Cabozantinib inhibits the tyrosine kinase activity of MET, VEGFR-1, -2 and -3, AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, FLT-3, and TIE-2. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment.<\/span><\/p>\n<p><strong><span data-preserver-spaces=\"true\">Absorption<\/span><\/strong><span data-preserver-spaces=\"true\">: Median time to peak Cabozantinib concentrations ranged from 3 to 4 hours post-dose. A 19% increase in the Cmax of Cabozantinib compared to a Cabozantinib capsule formulation was observed following a single 140 mg dose. A less than 10% difference in the AUC was observed between Cabozantinib and a Cabozantinib capsule formulation.<\/span><\/p>\n<p><strong><span data-preserver-spaces=\"true\">Distribution<\/span><\/strong><span data-preserver-spaces=\"true\">: The oral volume of distribution (Vz\/F) of Cabozantinib is approximately 319 L. It is highly protein-bound in human plasma (\u226599.7%).<\/span><\/p>\n<p><strong><span data-preserver-spaces=\"true\">Elimination<\/span><\/strong><span data-preserver-spaces=\"true\">: The predicted terminal half-life is approximately 99 hours, and the clearance (CL\/F) at a steady state is estimated to be 2.2 L\/hr.<\/span><\/p>\n<p><strong><span data-preserver-spaces=\"true\">Metabolism<\/span><\/strong><span data-preserver-spaces=\"true\">: It is a substrate of CYP3A4 in vitro.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">Excretion: Approximately 81% of the total administered radioactivity was recovered within a 48-day collection period following a single dose of radiolabeled 14 C- Cabozantinib in healthy subjects. Approximately 54% was recovered in feces and 27% in urine. Unchanged Cabozantinib accounted for 43% of the total radioactivity in feces and was not detectable in urine following a 72-hour collection.<\/span><\/p>\n<div id=\"dosage\">\n<h3 class=\"ac-header\">Dosage &amp; Administration:<\/h3>\n<p><strong><span data-preserver-spaces=\"true\">Recommended Dosage for Renal Cell Carcinoma<\/span><\/strong><span data-preserver-spaces=\"true\">: The recommended dosage is 60 mg once daily without food until the patient no longer experiences clinical benefit or experiences unacceptable toxicity.<\/span><\/p>\n<p><strong><span data-preserver-spaces=\"true\">Recommended Dosage for Hepatocellular Carcinoma<\/span><\/strong><span data-preserver-spaces=\"true\">: The recommended dosage is 60 mg daily without food until disease progression or unacceptable toxicity. Or as directed by the registered physicians.<\/span><\/p>\n<ul>\n<li><span data-preserver-spaces=\"true\">Stop treatment with Cabozantinib at least 28 days before the scheduled surgery, including dental surgery.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Do not substitute tablets with Cabozantinib capsules.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Do not administer with food. Administer at least 1 hour before or at least 2 hours after eating.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Swallow tablets whole. Do not crush tablets.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Do not take a missed dose within 12 hours of the next dose.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Modify the dose for certain patients with hepatic impairment and for patients taking drugs known to induce or inhibit CYP450 strongly.<\/span><\/li>\n<\/ul>\n<\/div>\n<\/div>\n<div id=\"interaction\">\n<h3 class=\"ac-header\">Interaction:<\/h3>\n<p><strong><span data-preserver-spaces=\"true\">Strong CYP3A4 Inhibitors<\/span><\/strong><span data-preserver-spaces=\"true\">: Coadministration of a Cabozantinib capsule formulation with a potent CYP3A4 inhibitor increased the exposure of Cabozantinib, which may increase the risk of exposure-related adverse reactions. Avoid coadministration with strong CYP3A4 inhibitors. Reduce the dosage if coadministration with potent CYP3A4 inhibitors cannot be avoided. Avoid grapefruit or grapefruit juice which may also increase the exposure to Cabozantinib.<\/span><\/p>\n<p><strong><span data-preserver-spaces=\"true\">Strong CYP3A Inducers<\/span><\/strong><span data-preserver-spaces=\"true\">: Coadministration of a Cabozantinib capsule formulation with a strong CYP3A4 inducer decreased the exposure of Cabozantinib, which may reduce efficacy. Avoid coadministration of Cabozantinib with strong CYP3A4 inducers. Increase the dosage of Cabozantinib if coadministration with strong CYP3A4 inducers cannot be avoided. Avoid St. John&#8217;s Wort which may also decrease the exposure of Cabozantinib.<\/span><\/p>\n<div id=\"side_effects\">\n<h3><span data-preserver-spaces=\"true\">How Cabozantinib is given:\u00a0<\/span><\/h3>\n<ul>\n<li><span data-preserver-spaces=\"true\">Cabozantinib is a pill taken by mouth.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Take Cabozantinib on an empty stomach<\/span><span data-preserver-spaces=\"true\"><b>. Do not eat for at least 2 hours before and at least 1 hour after taking Cabozantinib.<\/b><\/span><\/li>\n<li><span data-preserver-spaces=\"true\">It would be best if you did not drink grapefruit juice or eat grapefruit during treatment with Cabozantinib. It may change the amount of Cabozantinib in your blood.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Take Cabozantinib precisely as prescribed.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Swallow Cabozantinib capsules whole with at least 8 ounces of water. Do not crush, dissolve or open capsules.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Do not change your dose or stop Cabozantinib unless your health care provider tells you to.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">If you miss a dose and your next dose is due in:<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Take your next dose in less than 12 hours at the usual time. Do not make up the next dose.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Take the missed dose for twelve hours or more as soon as you remember. Take your following amount at the usual time.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Do not take more than one dose of Cabozantinib at one time. Call your health care provider right away if you take too much.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">The amount of Cabozantinib you receive depends on many factors, including your general health or other health problems and the type of cancer or condition being treated. Your doctor will determine your dose and schedule.<\/span><\/li>\n<\/ul>\n<div id=\"side_effects\">\n<h3 class=\"ac-header\">Side Effects:<\/h3>\n<p><span data-preserver-spaces=\"true\">Dizziness<\/span><span data-preserver-spaces=\"true\">,\u00a0<\/span><span data-preserver-spaces=\"true\">diarrhea<\/span><span data-preserver-spaces=\"true\">,\u00a0<\/span><span data-preserver-spaces=\"true\">nausea<\/span><span data-preserver-spaces=\"true\">,\u00a0<\/span><span data-preserver-spaces=\"true\">vomiting<\/span><span data-preserver-spaces=\"true\">,\u00a0<\/span><span data-preserver-spaces=\"true\">mouth<\/span><span data-preserver-spaces=\"true\">\u00a0sores,\u00a0<\/span><span data-preserver-spaces=\"true\">constipation<\/span><span data-preserver-spaces=\"true\">,\u00a0<\/span><span data-preserver-spaces=\"true\">stomach pain<\/span><span data-preserver-spaces=\"true\">, tiredness,\u00a0<\/span><span data-preserver-spaces=\"true\">weakness<\/span><span data-preserver-spaces=\"true\">,\u00a0<\/span><span data-preserver-spaces=\"true\">weight loss<\/span><span data-preserver-spaces=\"true\">, decreased appetite, taste changes, hoarseness, and lightening of\u00a0<\/span><span data-preserver-spaces=\"true\">hair<\/span><span data-preserver-spaces=\"true\">\u00a0color may occur. Tell your doctor or pharmacist promptly if any of these effects persist or worsen.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">Temporary\u00a0<\/span><span data-preserver-spaces=\"true\">hair loss<\/span><span data-preserver-spaces=\"true\">\u00a0may occur. Average\u00a0<\/span><span data-preserver-spaces=\"true\">hair<\/span><span data-preserver-spaces=\"true\">\u00a0growth should return after treatment has ended.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">People using this\u00a0<\/span><a class=\"editor-rtfLink\" href=\"https:\/\/www.webmd.com\/drugs\/index-drugs.aspx\" target=\"_blank\" rel=\"noopener\"><span data-preserver-spaces=\"true\">medication<\/span><\/a><span data-preserver-spaces=\"true\">\u00a0may have serious side effects. However, you have been prescribed this drug because your doctor has judged that your benefit is greater than the risk of side effects. Careful monitoring by your doctor may decrease your stake.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">Cabozantinib may rarely cause severe, possibly fatal,\u00a0<\/span><span data-preserver-spaces=\"true\">stomach<\/span><span data-preserver-spaces=\"true\">\/abdominal side effects such as a hole in the gut wall (perforation) or an abnormal tunnel or connection in your body (<\/span><span data-preserver-spaces=\"true\">fistula<\/span><span data-preserver-spaces=\"true\">). It can also rarely cause severe, possibly fatal, bleeding. Do not take this medication if you have severe bleeding. Get medical help right away if you have unusual or easy bruising\/bleeding, signs of\u00a0<\/span><span data-preserver-spaces=\"true\">stomach<\/span><span data-preserver-spaces=\"true\">\/intestinal bleeding (such as bloody\/black\/tarry stools, stomach\/<\/span><span data-preserver-spaces=\"true\">abdominal pain<\/span><span data-preserver-spaces=\"true\">, bloody vomit, vomit that looks like coffee grounds), fever, chills, sudden\/severe back pain, severe vomiting\/<\/span><span data-preserver-spaces=\"true\">diarrhea<\/span><span data-preserver-spaces=\"true\">, or if you are\u00a0<\/span><span data-preserver-spaces=\"true\">coughing<\/span><span data-preserver-spaces=\"true\">\/gagging\/choking when eating or drinking, or\u00a0<\/span><span data-preserver-spaces=\"true\">coughing up blood<\/span><span data-preserver-spaces=\"true\">.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">This medication may raise your\u00a0<\/span><span data-preserver-spaces=\"true\">blood pressure<\/span><span data-preserver-spaces=\"true\">. Check your\u00a0<\/span><span data-preserver-spaces=\"true\">blood<\/span><span data-preserver-spaces=\"true\">\u00a0pressure regularly and tell your doctor if the results are high. Your doctor may control your blood pressure with medication.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">Tell your doctor right away if you have any severe side effects, including redness\/pain\/swelling\/<\/span><span data-preserver-spaces=\"true\">blisters<\/span><span data-preserver-spaces=\"true\">\u00a0on the palms of your hands or soles of your feet, frothy urine, swelling of the hands\/feet, cold intolerance, slow heartbeat, signs of a low\u00a0<\/span><span data-preserver-spaces=\"true\">calcium<\/span><span data-preserver-spaces=\"true\">\u00a0blood level (such as severe\u00a0<\/span><span data-preserver-spaces=\"true\">muscle spasms<\/span><span data-preserver-spaces=\"true\">, mental\/mood changes,\u00a0<\/span><span data-preserver-spaces=\"true\">seizures<\/span><span data-preserver-spaces=\"true\">), symptoms of a jawbone problem (such as\u00a0<\/span><span data-preserver-spaces=\"true\">jaw pain<\/span><span data-preserver-spaces=\"true\">,\u00a0<\/span><span data-preserver-spaces=\"true\">toothache<\/span><span data-preserver-spaces=\"true\">, gum sores), poor wound healing, signs of\u00a0<\/span><span data-preserver-spaces=\"true\">liver problems<\/span><span data-preserver-spaces=\"true\">\u00a0(such as yellowing\u00a0<\/span><span data-preserver-spaces=\"true\">eyes<\/span><span data-preserver-spaces=\"true\">\/<\/span><span data-preserver-spaces=\"true\">skin<\/span><span data-preserver-spaces=\"true\">,\u00a0<\/span><span data-preserver-spaces=\"true\">dark urine<\/span><span data-preserver-spaces=\"true\">).<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">Cabozantinib may also rarely cause a severe\u00a0<\/span><span data-preserver-spaces=\"true\">brain<\/span><span data-preserver-spaces=\"true\">\u00a0condition. Get medical help immediately if you develop\u00a0<\/span><span data-preserver-spaces=\"true\">headaches<\/span><span data-preserver-spaces=\"true\">, seizures,\u00a0<\/span><span data-preserver-spaces=\"true\">vision<\/span><span data-preserver-spaces=\"true\">\u00a0changes, confusion, or thinking problems.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">This medication may rarely cause serious problems (such as\u00a0<\/span><span data-preserver-spaces=\"true\">heart attacks<\/span><span data-preserver-spaces=\"true\">, strokes,\u00a0<\/span><span data-preserver-spaces=\"true\">deep vein thrombosis<\/span><span data-preserver-spaces=\"true\">,\u00a0<\/span><span data-preserver-spaces=\"true\">pulmonary embolism<\/span><span data-preserver-spaces=\"true\">) from\u00a0<\/span><span data-preserver-spaces=\"true\">blood clots<\/span><span data-preserver-spaces=\"true\">. Get medical help right away if you have any severe side effects, including chest\/jaw\/left arm pain, unusual\u00a0<\/span><span data-preserver-spaces=\"true\">sweating<\/span><span data-preserver-spaces=\"true\">, sudden\/severe\u00a0<\/span><span data-preserver-spaces=\"true\">headache<\/span><span data-preserver-spaces=\"true\">, weakness on one side of your body, confusion, trouble speaking, sudden vision changes (such as partial\/complete blindness), pain\/redness\/swelling in your arms\/legs, tingling\/weakness\/numbness in your face\/arms\/legs,\u00a0<\/span><span data-preserver-spaces=\"true\">trouble breathing<\/span><span data-preserver-spaces=\"true\">,\u00a0<\/span><span data-preserver-spaces=\"true\">coughing<\/span><span data-preserver-spaces=\"true\">\u00a0up blood, sudden dizziness\/<\/span><span data-preserver-spaces=\"true\">fainting<\/span><span data-preserver-spaces=\"true\">.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">This medication may lower your ability to fight infections. This may make you more likely to get a serious (rarely fatal) condition or make any infection you have worse. Tell your doctor immediately if you have any signs of infection (such as\u00a0<\/span><span data-preserver-spaces=\"true\">a sore throat<\/span><span data-preserver-spaces=\"true\">\u00a0that doesn&#8217;t go away, fever, chills,\u00a0<\/span><span data-preserver-spaces=\"true\">cough<\/span><span data-preserver-spaces=\"true\">).<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">When used with the medication\u00a0<\/span><span data-preserver-spaces=\"true\">nivolumab<\/span><span data-preserver-spaces=\"true\">, cabozantinib may cause your\u00a0<\/span><span data-preserver-spaces=\"true\">adrenal glands<\/span><span data-preserver-spaces=\"true\">\u00a0not to work well. Tell your doctor immediately if you have any signs of your adrenal glands not working well (such as loss of appetite, unusual tiredness,\u00a0<\/span><span data-preserver-spaces=\"true\">or weight<\/span><span data-preserver-spaces=\"true\">\u00a0loss).<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">A severe\u00a0<\/span><span data-preserver-spaces=\"true\">allergic reaction<\/span><span data-preserver-spaces=\"true\">\u00a0to this drug is rare. However, get medical help immediately if you notice any symptoms of a severe\u00a0<\/span><span data-preserver-spaces=\"true\">allergic reaction<\/span><span data-preserver-spaces=\"true\">, including\u00a0<\/span><span data-preserver-spaces=\"true\">rash<\/span><span data-preserver-spaces=\"true\">,\u00a0<\/span><span data-preserver-spaces=\"true\">itching<\/span><span data-preserver-spaces=\"true\">\/swelling (especially of the face\/<\/span><span data-preserver-spaces=\"true\">tongue<\/span><span data-preserver-spaces=\"true\">\/throat), severe dizziness,\u00a0<\/span><span data-preserver-spaces=\"true\">or trouble breathing<\/span><span data-preserver-spaces=\"true\">.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">This is not a complete list of possible side effects. Contact your doctor or pharmacist if you notice other effects not listed above.<\/span><\/p>\n<\/div>\n<div class=\"ac-body\">\n<div id=\"pregnancy_cat\">\n<h4 class=\"ac-header\">Pregnancy &amp; Lactation:<\/h4>\n<p><strong><span data-preserver-spaces=\"true\">Pregnancy<\/span><\/strong><span data-preserver-spaces=\"true\">: Cabozantinib can cause fetal harm when administered to a pregnant woman. There are no available data on pregnant women to inform the drug-associated risk.<\/span><\/p>\n<p><strong><span data-preserver-spaces=\"true\">Lactation<\/span><\/strong><span data-preserver-spaces=\"true\">: There is no information regarding the presence of Cabozantinib, its metabolites in human milk, or its effects on the breastfed child or milk production. Because of the potential for severe adverse reactions in breastfed children, women should be advised not to breastfeed during treatment with Cabozantinib and for four months after the final dose.<\/span><\/p>\n<p><strong><span data-preserver-spaces=\"true\">Contraception<\/span><\/strong><span data-preserver-spaces=\"true\">: Cabozantinib can cause fetal harm when administered to a pregnant woman.<\/span><\/p>\n<p><strong><span data-preserver-spaces=\"true\">Females<\/span><\/strong><span data-preserver-spaces=\"true\">: Females of reproductive potential should be advised to use effective contraception during treatment with Cabozantinib and for four months after the final dose.<\/span><\/p>\n<p><strong><span data-preserver-spaces=\"true\">Infertility<\/span><\/strong><span data-preserver-spaces=\"true\">: Females and Males: Based on animal findings, Cabozantinib may impair fertility in females and males of reproductive potential.<\/span><\/p>\n<div id=\"precautions\">\n<h3 class=\"ac-header\">Precautions &amp; Warnings:<\/h3>\n<p><strong><span data-preserver-spaces=\"true\">Hemorrhage<\/span><\/strong><span data-preserver-spaces=\"true\">: Severe and fatal hemorrhages occurred with Cabozantinib. Discontinue Cabozantinib for Grade 3 or 4 hemorrhage. Do not administer Cabozantinib to patients with a recent history of bleeding, including hemoptysis, hematemesis, or melena.<\/span><\/p>\n<p><strong><span data-preserver-spaces=\"true\">Perforations and Fistulas<\/span><\/strong><span data-preserver-spaces=\"true\">: Fistulas, including fatal cases, occurred in 1% of Cabozantinib-treated patients. Gastrointestinal (GI) perforations occurred in 1% of Cabozantinib-treated patients, including fatal cases. Monitor patients for signs and symptoms of fistulas and perforations, including abscess and sepsis. Discontinue Cabozantinib in patients who experience a fistula that cannot be appropriately managed or a GI perforation.<\/span><\/p>\n<p><strong><span data-preserver-spaces=\"true\">Thrombotic Events<\/span><\/strong><span data-preserver-spaces=\"true\">: Cabozantinib increased the risk of thrombotic events. Venous thromboembolism occurred in 7% (including 4% pulmonary embolism), and arterial thromboembolism occurred in 2% of Cabozantinib<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">-treated patients. Fatal thrombotic events occurred in Cabozantinib-treated patients. Discontinue Cabozantinib in patients who develop an acute myocardial infarction or arterial severe or venous thromboembolic events that require medical intervention.<\/span><\/p>\n<p><strong><span data-preserver-spaces=\"true\">Hypertension and Hypertensive Crisis<\/span><\/strong><span data-preserver-spaces=\"true\">: Cabozantinib can cause hypertension, including hypertensive crisis. Do not initiate Cabozantinib in patients with uncontrolled hypertension. Monitor blood pressure regularly during Cabozantinib treatment. Withhold Cabozantinib for hypertension that is not adequately controlled with medical Management; when controlled, resume Cabozantinib at a reduced dose. Discontinue Cabozantinib for severe hypertension that cannot be controlled with antihypertensive therapy or for hypertensive crisis.<\/span><\/p>\n<p><strong><span data-preserver-spaces=\"true\">Diarrhea<\/span><\/strong><span data-preserver-spaces=\"true\">: Diarrhea occurred in 63% of patients treated with Cabozantinib. Withhold Cabozantinib until improvement to Grade 1 and resume Cabozantinib at a reduced dose for intolerable Grade 2 diarrhea, Grade 3 diarrhea that cannot be managed with standard antidiarrheal treatments, or Grade 4 diarrhea.<\/span><\/p>\n<p><strong><span data-preserver-spaces=\"true\">Palmar-Plantar Erythrodysesthesia<\/span><\/strong><span data-preserver-spaces=\"true\">: Palmar-plantar erythrodysesthesia (PPE) occurred in 44% of patients treated with Cabozantinib. Withhold Cabozantinib until improvement to Grade 1 and resume Cabozantinib at a reduced dose for intolerable Grade 2 PPE or Grade 3 PPE.<\/span><\/p>\n<p><strong><span data-preserver-spaces=\"true\">Proteinuria<\/span><\/strong><span data-preserver-spaces=\"true\">: Proteinuria was observed in 7% of patients receiving Cabozantinib. Monitor urine protein regularly during Cabozantinib treatment. Discontinue Cabozantinib in patients who develop nephrotic syndrome.<\/span><\/p>\n<p><strong><span data-preserver-spaces=\"true\">Osteonecrosis of the Jaw<\/span><\/strong><span data-preserver-spaces=\"true\">: Osteonecrosis of the jaw (ONJ) occurred in &lt;1% of patients treated with Cabozantinib. ONJ can manifest as jaw pain, osteomyelitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration or decay, persistent jaw pain, or slow healing of the mouth or jaw after dental surgery. Perform an oral examination before initiation of Cabozantinib and periodically during Cabozantinib. Advise patients regarding good oral hygiene practices. Withhold Cabozantinib for at least 28 days before scheduled dental surgery or invasive dental procedures, if possible. Withhold Cabozantinib for the development of ONJ until complete resolution.<\/span><\/p>\n<p><strong><span data-preserver-spaces=\"true\">Wound Complications<\/span><\/strong><span data-preserver-spaces=\"true\">: Wound complications have been reported with Cabozantinib. Stop Cabozantinib at least 28 days before a scheduled surgery. Resume Cabozantinib after surgery based on clinical judgment of adequate wound healing. Withhold Cabozantinib in patients with dehiscence or wound healing complications requiring medical intervention.<\/span><\/p>\n<p><strong><span data-preserver-spaces=\"true\">Reversible Posterior Leukoencephalopathy Syndrome<\/span><\/strong><span data-preserver-spaces=\"true\">: Reversible Posterior Leukoencephalopathy Syndrome (RPLS), a syndrome of subcortical vasogenic edema diagnosed by characteristic findings on MRI, can occur with Cabozantinib. Evaluate RPLS in any patient presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue Cabozantinib in patients who develop RPLS.<\/span><\/p>\n<p><strong><span data-preserver-spaces=\"true\">Embryo-Fetal Toxicity<\/span><\/strong><span data-preserver-spaces=\"true\">: Based on data from animal studies and its mechanism of action, Cabozantinib can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with Cabozantinib and for four months after the last dose.<\/span><\/p>\n<div id=\"overdose_effects\">\n<h4 class=\"ac-header\">Overdose Effects:<\/h4>\n<p>One case of over dosage was reported following administration of another formulation of cabozantinib; a patient inadvertently took twice the intended dose for nine days. The patient suffered Grade 3 memory impairment, Grade 3 mental status changes, Grade 3 cognitive disturbance, Grade 2 weight loss, and Grade 1 increase in BUN. The extent of recovery was not documented.<\/p>\n<h4>Self-Care Tips:<\/h4>\n<ul>\n<li><span data-preserver-spaces=\"true\">Drink at least two to three quarts of fluid every 24 hours unless instructed otherwise.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">You may be at risk of infection, so try to avoid crowds or people with colds and immediately report fever or any other signs of infection to your health care provider.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Wash your hands often.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Monitor your blood pressure and notify your physician if blood pressure is elevated or if you develop a severe headache, lightheadedness, or other neurological symptoms (numbness, tingling, difficulty speaking).<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">To help treat\/prevent mouth sores, use a soft toothbrush, and rinse three times a day with one teaspoon of baking soda mixed with 8 ounces of water.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Use an electric razor and a soft toothbrush to minimize bleeding.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Avoid contact sports or activities that could cause injury.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Take anti-nausea medications as your doctor prescribes and eat small, frequent meals to reduce nausea.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Follow a regimen of anti-diarrhea medication as prescribed by your health care professional.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Eat foods that may help reduce diarrhea<\/span><span data-preserver-spaces=\"true\">.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Prevention of hand-foot syndrome. Modification of normal activities of daily living to reduce friction and heat exposure to hands and feet for about a week after treatment.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Keep palms of hands and soles of feet moist using emollients.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Avoid sun exposure. Wear SPF 15 (or higher) sunblock and protective clothing.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">In general, drinking alcoholic beverages should be kept to a minimum or avoided completely. It would help if you discussed this with your doctor.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Get plenty of rest.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Maintain good nutrition.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">Maintain physical activity as tolerated.<\/span><\/li>\n<li><span data-preserver-spaces=\"true\">If you experience symptoms or side effects, discuss them with your health care team. They can prescribe medications and offer other practical suggestions for managing such problems.\u00a0<\/span><\/li>\n<\/ul>\n<div id=\"storage_conditions\">\n<h4 class=\"ac-header\">Storage Conditions:<\/h4>\n<section class=\"section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-xs-12 col-sm-12 col-md-12 col-lg-12\">\n<div class=\"generic-data-container en\">\n<div>\n<div class=\"ac-body\">Store below 30\u00b0C in a cool and dry place, away from sunlight. Keep out of reach of children.<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div><\/div>\n<div><\/div>\n<div id=\"indications\">\n<div id=\"interaction\">\n<div id=\"side_effects\">\n<p><span style=\"color: #800000;\"><strong><span style=\"color: #000000;\">To see more Cabozantinib medicine <span style=\"color: #ff0000;\"><a style=\"color: #ff0000;\" href=\"https:\/\/emergencydrug.com\/product-tag\/cabozantinib\/\">click here<\/a>.<\/span><\/span><\/strong><\/span><\/p>\n<\/div>\n<div class=\"ac-body\"><\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p><span style=\"font-weight: 400;\">Cabozantinib is a targeted therapy. It is an oral receptor tyrosine kinase inhibitor. Cabozantinib treats metastatic medullary thyroid cancer (MTC), advanced renal cell carcinoma, and patients with hepatocellular cancer (HCC) who have previously received sorafenib.\u00a0<\/span><\/p>\n","protected":false},"featured_media":3020,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"mc_generic":[363],"brands":[404],"product_cat":[439],"product_tag":[312,289,437],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/emergencydrug.com\/ar\/wp-json\/wp\/v2\/product\/2232"}],"collection":[{"href":"https:\/\/emergencydrug.com\/ar\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/emergencydrug.com\/ar\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/emergencydrug.com\/ar\/wp-json\/wp\/v2\/comments?post=2232"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/emergencydrug.com\/ar\/wp-json\/wp\/v2\/media\/3020"}],"wp:attachment":[{"href":"https:\/\/emergencydrug.com\/ar\/wp-json\/wp\/v2\/media?parent=2232"}],"wp:term":[{"taxonomy":"mc_generic","embeddable":true,"href":"https:\/\/emergencydrug.com\/ar\/wp-json\/wp\/v2\/mc_generic?post=2232"},{"taxonomy":"brands","embeddable":true,"href":"https:\/\/emergencydrug.com\/ar\/wp-json\/wp\/v2\/brands?post=2232"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/emergencydrug.com\/ar\/wp-json\/wp\/v2\/product_cat?post=2232"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/emergencydrug.com\/ar\/wp-json\/wp\/v2\/product_tag?post=2232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}